Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Breanne M, Barrow"'
Autor:
Nathalie Esser, Christine Schmidt, Breanne M. Barrow, Laura Cronic, Daryl J. Hackney, Stephen M. Mongovin, Meghan F. Hogan, Andrew T. Templin, Joseph J. Castillo, Rebecca L. Hull, Sakeneh Zraika
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Treatment of heart failure with the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan improved glycemic control in individuals with type 2 diabetes. The relative contribution of neprilysin inhibition versus angiotensin II receptor antago
Externí odkaz:
https://doaj.org/article/2ca52c5595b6419c9d324310bf524e62
Publikováno v:
Journal of Molecular Endocrinology. 69:R63-R79
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Following initial infection of airway epithelia, SARS-CoV-2 invades a wide range of cells in multiple organs, including pancreati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ab0a51e26e3de1bd5ef781a64de536
https://doi.org/10.1530/jme-21-0282
https://doi.org/10.1530/jme-21-0282
Autor:
Nathalie, Esser, Stephen M, Mongovin, Jacqueline, Parilla, Breanne M, Barrow, Thomas O, Mundinger, Brendy S, Fountaine, Megan J, Larmore, Joseph J, Castillo, Rehana, Akter, Rebecca L, Hull, Sakeneh, Zraika
Publikováno v:
Am J Physiol Endocrinol Metab
Type 2 diabetes is associated with the upregulation of neprilysin, a peptidase capable of cleaving glucoregulatory peptides such as glucagon-like peptide-1 (GLP-1). In humans, use of the neprilysin inhibitor sacubitril in combination with an angioten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c8fb8c338ce71d519f28c580d56881f
https://pubmed.ncbi.nlm.nih.gov/35128957
https://pubmed.ncbi.nlm.nih.gov/35128957
Publikováno v:
Journal of Diabetes Research, Vol 2018 (2018)
Loss of first-phase insulin release is an early pathogenic feature of type 2 diabetes (T2D). Various mouse models exist to study T2D; however, few recapitulate the early β-cell defects seen in humans. We sought to develop a nongenetic mouse model of
Externí odkaz:
https://doaj.org/article/e09a644f4b1642b5a3e19ab50e3c96d0
Autor:
Christine R. Schmidt, Nathalie Esser, Daryl J. Hackney, Steve M. Mongovin, Sakeneh Zraika, Breanne M. Barrow, Laura Cronic, Rebecca L. Hull
Publikováno v:
Diabetes. 69
In type 2 diabetes, HbA1c decreases upon treatment of heart failure with the angiotensin receptor-neprilysin (NEP) inhibitor LCZ696 (LCZ). We sought to determine whether the components of LCZ, the NEP inhibitor sacubitril (SAC) and angiotensin recept
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5386c885d7be08821e9bc60ae2f4b21
https://doi.org/10.2337/db20-1797-p
https://doi.org/10.2337/db20-1797-p
Autor:
Andrew A. Welch, Breanne M. Barrow, Sakeneh Zraika, Bela P. Ruzsicska, Daniel P. Raleigh, Gurkirat S. Brar, Ryan Griesbach, Matthew D. Watson, Edwina Choung
Publikováno v:
Diabetes
Recent work has renewed interest in therapies targeting the renin-angiotensin system (RAS) to improve β-cell function in type 2 diabetes. Studies show that generation of angiotensin-(1–7) by ACE2 and its binding to the Mas receptor (MasR) improves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a0eb3f27bbed825e8627d117993c6e7
https://doi.org/10.2337/db16-1318
https://doi.org/10.2337/db16-1318
Publikováno v:
Diabetes. 68
Increased activity of the ubiquitous peptidase neprilysin in obesity and type 2 diabetes (T2D) is associated with impaired glucose homeostasis, and its inhibition has been shown to improve β-cell function. Neprilysin cleaves and inactivates insulino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e306fa07e1aa1dd3b6c79f42a67f6abe
https://doi.org/10.2337/db19-1829-p
https://doi.org/10.2337/db19-1829-p
Publikováno v:
Islets. 10(5)
Neprilysin, a widely expressed peptidase upregulated in type 2 diabetes, is capable of cleaving and inactivating the insulinotropic glucagon-like peptide-1 (GLP-1). Like dipeptidyl peptidase-4 (DPP-4), inhibition of neprilysin activity under diabetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b14ac8f6ade1c4242cda0c59ada1ce64
https://pubmed.ncbi.nlm.nih.gov/30142012
https://pubmed.ncbi.nlm.nih.gov/30142012
Publikováno v:
Diabetes. 67
Neprilysin (NEP) is a ubiquitous peptidase whose plasma activity in humans and rodents increases in conditions associated with type 2 diabetes (T2D). In high fat-fed mice, increased plasma NEP activity correlates with insulin resistance and impaired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d13ae6f427ac818ff913ccf42d702bec
https://doi.org/10.2337/db18-1825-p
https://doi.org/10.2337/db18-1825-p
Publikováno v:
Journal of Diabetes Research, Vol 2018 (2018)
Journal of Diabetes Research
Journal of Diabetes Research
Loss of first-phase insulin release is an early pathogenic feature of type 2 diabetes (T2D). Various mouse models exist to study T2D; however, few recapitulate the early β-cell defects seen in humans. We sought to develop a nongenetic mouse model of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eeae4a651ff2913cc67f5a9790a4238
https://doaj.org/article/e09a644f4b1642b5a3e19ab50e3c96d0
https://doaj.org/article/e09a644f4b1642b5a3e19ab50e3c96d0